Fiscal consequences of changes in morbidity and mortality attributed to rotavirus immunisation.
Changes in population health status are known to influence government fiscal transfers both in terms of lost tax revenue and increased expenditure for health and social services. To estimate the fiscal impact of changes in morbidity and mortality attributed to rotavirus immunisation, we developed a government perspective model to estimate discounted net tax revenue for Ghana and Vietnam. The model derived the impact of rotavirus morbidity and mortality on lifetime productive capacity and related tax transfers, and demand for government transfers in relation to education and healthcare in immunised and non-immunised cohorts. The discounted age-specific net tax revenue was derived by deducting transfers from gross taxes and discounting for time preference. In Ghana, taking into account immunisation costs, tax and transfers, the estimated net discounted tax for the immunised cohort was estimated to generate $2.6 billion in net taxes up to age 65. In Vietnam, the net revenue attributed to the immunised cohort reached $55.17 billion suggesting an incremental benefit of approximately $29 million. We posit that the government perspective fiscal framework described here is a valid approach for estimating how governments benefit from investments in immunisation that can be considered supplementary to conventional cost-effectiveness approaches for defining value.
Unit of PharmacoEpidemiology & PharmacoEconomics, Department of Pharmacy, University of Groningen, The Netherlands; Global Market Access Solutions (GMAS), St-Prex, Switzerland.
Nikolaos
N
Kotsopoulos
Mark P
MP
Connolly
Maarten J
MJ
Postma
Raymond C W
RC
Hutubessy
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D002675:Child, Preschool; D003365:Costs and Cost Analysis; D005260:Female; D005869:Ghana / Q000453:epidemiology; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008297:Male; D008875:Middle Aged; D012400:Rotavirus Infections / Q000191:economics* / Q000453:epidemiology / Q000401:mortality / Q000517:prevention & control*; D022243:Rotavirus Vaccines / Q000008:administration & dosage / Q000191:economics* / Q000276:immunology*; D016019:Survival Analysis; D014744:Vietnam / Q000453:epidemiology; D055815:Young Adult
D022243:Rotavirus Vaccines
Developing countries; Fiscal analysis; Immunisation; Population health; Rotavirus; Vaccines